Apolipoprotein B-100-reactive T-cell receptor (ApoB-TCR)

Apolipoprotein B-100-reactive T-cell receptors (ApoB-TCRs) are specialized antigen receptors found on the surface of T cells that specifically recognize peptide fragments of Apolipoprotein B-100, the primary protein component of low-density lipoprotein (LDL) (Kimura et al., 2018, Nature Medicine). In the context of atherosclerosis, these TCRs are predominantly expressed on pro-atherogenic effector T cells, such as Th1 and Th17 cells, which infiltrate the arterial wall and respond to modified LDL trapped in the subendothelial space (Wolf and Ley, 2019, Circulation Research). Upon binding to ApoB peptides presented by major histocompatibility complex class II (MHC-II) molecules on antigen-presenting cells, these TCRs trigger the release of pro-inflammatory cytokines like interferon-gamma, which promotes plaque progression and instability (Saigusa et al., 2020, Nature Reviews Cardiology). Conversely, targeting these TCRs through antigen-specific immunotherapy, such as peptide vaccines or tolerogenic dendritic cells, aims to shift the immune response toward a regulatory phenotype (Tregs) to suppress vascular inflammation. This makes the ApoB-TCR a critical focal point for precision medicine strategies designed to treat cardiovascular disease by modulating the underlying autoimmune-like response to LDL. Research into TCR sequencing has identified specific conserved motifs in these receptors, suggesting they could serve as both therapeutic targets and diagnostic biomarkers for atherosclerotic risk.

Other names

LDL-reactive T-cell receptorApoB-specific TCRAtherogenic T-cell receptorLow-density lipoprotein-reactive T-cell receptorApolipoprotein B-100-specific T-cell receptor

Antigen-specific modulation of T-cell activation through the recognition of Apolipoprotein B-100 peptides presented on MHC-II, leading to either pro-inflammatory effector responses or the induction of regulatory T-cell (Treg) mediated tolerance.